Blue Cross Blue Shield TN coronavirus testing Coverage | OpenPayer
Currentblue cross blue shield - tennesseePolicy N/A
Coronavirus Testing in the Outpatient Setting
Outlines outpatient coverage criteria and reimbursement rules for SARS-CoV-2 and other coronavirus testing for BlueCross BlueShield of Tennessee members, including which tests meet or do not meet coverage and limits on use.
Policy Summary
Payerblue cross blue shield - tennessee
PolicyCoronavirus Testing in the Outpatient Setting
Policy CodePolicy N/A
Change TypeNo material changes
Effective Date
Next Review Date
Key ActionUse targeted testing: cover NAAT for symptomatic individuals and asymptomatic exposed persons (except within 90 days of prior infection); antigen tests covered every 48 hours for symptomatic persons; antigen panels covered up to 5 antigens.
No material clinical or coverage changes in this revision.
up to 5antigens allowed on antigen panel testing that meets coverage
6+antigens on panel that do NOT meet coverage
48 hrsfrequency for covered antigen tests (symptomatic)
90 daysrecent prior infection exclusion window
1single code reimbursed per DOS
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
0.41%pre-op PCR positive rate (study)
Coverage Criteria for SARS-CoV-2 and Coronavirus Testing
Covered indications
Covered when ANY of the following are met
Targeted nucleic acid testing (COVID-19): Meets coverage for individuals displaying signs and symptoms of possible COVID-19 infection (see Note 1).See Note 1 for symptom list
chunk 2
Asymptomatic with known exposure: Meets coverage for asymptomatic individuals with known exposure to COVID-19, except when the individual had a previous COVID-19 infection within the last 90 days.90 days since prior infection
chunk 2
SARS or MERS symptomatic with travel/exposure: Targeted nucleic acid testing (e.g., RT-PCR) meets coverage for individuals with signs or symptoms of SARS or MERS who traveled to endemic areas or were exposed to persons with SARS or MERS.
chunks 2 and 3
MIS-C / MIS-A / PASC support: Nucleic acid amplification testing and host antibody serology testing meet coverage to support diagnosis of MIS-C, MIS-A, or post-acute sequelae of SARS-CoV-2 infection (PASC/Long COVID) when used to inform clinical management.
chunk 3
Symptomatic antigen testing frequency: For symptomatic individuals, antigen-detecting diagnostic tests for SARS-CoV-2 meet coverage once every 48 hours.48 hours
chunk 3
Antigen panel testing: For individuals with signs and symptoms of a respiratory tract infection, antigen panel testing of up to 5 antigens meets coverage.<=5 antigens
chunk 3
Not medically necessary / Not covered
Not covered (does not meet coverage criteria)
Reinfection WGS: Whole genome sequencing of paired specimens from distinct lineages for diagnosis of SARS-CoV-2 reinfection does NOT meet coverage.
chunk 3
Antigen panel >5: Antigen panel testing of 6 or more antigens does NOT meet coverage.>=6 antigens
chunk 3
Host antibody testing general: Host antibody serology testing does NOT meet coverage for situations not explicitly listed as covered (not appropriate for diagnosing acute infection in the first 2 weeks).
chunk 3
SARS-CoV-2 genotyping does NOT meet coverage in the outpatient setting.
Evidence-based coverage considerations
Clinical interpretation and utility conditions reported in the literature
Antibody testing time-dependence: Antibody tests (IgG, IgM) have limited sensitivity in early infection and substantially higher sensitivity after ~14 days post-symptom onset; IgG seroconversion is common after 14 days and serology is most useful for detecting past infection and for seroepidemiologic purposes rather than diagnosing acute infection.>14 days post symptom onset
Sources report increasing sensitivity over time (examples in Kweon et al., Fox et al.).
Antigen test utility and limits: Antigen tests can rapidly detect viral proteins and may identify individuals with moderate-to-high viral loads, but sensitivity is variable and generally lower than NAAT; negative antigen results may require confirmatory molecular testing when clinical suspicion is high.first ~5 days of symptom onset for some assays
Reported antigen sensitivities vary widely across studies.
Test performance variability and quality concerns:
COVID-19 self-testing (WHO recommendations)
Covered when aligned with WHO guidance and local context
WHO self-testing recommendations: Self-testing with WHO-quality-assured Ag-RDTs should be offered in addition to professional testing, be voluntary (not mandatory), accompanied by clear messaging and linkage to care, and tests should meet WHO minimum performance (≥80% sensitivity and ≥97% specificity among symptomatic individuals); local adaptation to epidemiology and resource availability is required.>=80% sensitivity; >=97% specificity
Costs should not be borne by students/workers in certain settings and self-testing can be used for diagnostic or screening purposes with appropriate follow-up.
NAAT vs Antigen testing (CDC/NIH/IDSA guidance)
Testing modality selection and repeat testing logic
Preferred testing: NAATs (including PCR) are the most sensitive and specific tests for current infection; antigen tests are rapid with high specificity but lower sensitivity, particularly in asymptomatic persons.
NAAT may detect RNA up to 90 days; interpret in clinical context.
When to use NAAT vs antigen: If no prior positive test within 90 days an individual may choose NAAT or antigen; if an individual had a positive test within the past 30 days (or 31–90 days), CDC/NIH recommend preferential use of antigen tests rather than repeat NAAT in many circumstances.90-day window referenced
NIH/CDC distinctions by time since prior positive are included.
Repeat testing: Repeat NAAT is not routinely recommended; repeat testing may be considered when clinical suspicion persists or specimen quality is poor — if repeated, generally 24–48 hours after the initial test; CDC recommends serial antigen testing (two negatives for symptomatic or three for asymptomatic, 48 hours apart) to exclude infection.
MIS-C and MIS-A case definitions and reporting (CDC criteria)
Case classification and required criteria
Case classification: MIS-C cases can be classified as Confirmed (clinical and laboratory criteria), Probable (clinical and epidemiologic linkage), or Suspect (vital records); MIS-A uses analogous classifications for adults ≥21 years.
CDC case-classification tiers referenced.
MIS-C clinical criteria: MIS-C requires fever (≥38.0°C) AND clinical severity requiring hospitalization or resulting in death AND elevated inflammation (eg, CRP ≥3.0 mg/dL) AND new onset manifestations in at least two organ systems (cardiac, mucocutaneous, shock, gastrointestinal, hematologic) AND no alternative diagnosis AND evidence of current or recent SARS-CoV-2 infection or exposure (within 60 days).fever >=3 days noted in evaluation guidance
Laboratory confirmation can include positive self-administered antigen or molecular tests.
MIS-A clinical and lab criteria: MIS-A requires hospitalization ≥24 hours plus fever and an illness meeting clinical and laboratory thresholds (at least three clinical findings with at least one primary such as severe cardiac illness or rash with conjunctivitis) together with evidence of SARS-CoV-2 infection and systemic inflammation (≥2 elevated inflammatory markers).
Long COVID / Post-COVID conditions (CDC guidance)
Diagnosis and evaluation principles
Definition and diagnosis: Long COVID (post-COVID conditions) is an infection-associated condition present at least 3 months after SARS-CoV-2 infection; diagnosis is clinical using history and examination and may include directed testing, but no laboratory test definitively establishes the diagnosis and positive viral or serologic tests are not required.>=3 months
Objective labs should not be the sole measure of patient status.
Common symptoms include fatigue, post-exertional malaise, cognitive difficulties, dyspnea, persistent headache, sleep disturbance, smell/taste problems, GI symptoms, and palpitations/lightheadedness.
Symptom spectrum is broad and variable.
Guideline-based testing coverage criteria
Summary of guideline-based coverage stance for SARS-CoV-2 NAAT and serology
Testing of symptomatic patients: Symptomatic patients should be tested for SARS-CoV-2; symptomatic defined as at least one common compatible symptom. Repeat testing is not routinely suggested but may be considered for new/worsening symptoms or poor specimen collection; when done repeat testing is generally 24–48 hours after the initial test.24-48 hours for repeat when indicated
IDSA/NIH guidance summarized.
Asymptomatic individuals with known/suspected exposure: IDSA suggests NAAT or antigen testing in asymptomatic individuals with known or suspected exposure; testing is recommended at least 5 days after exposure or immediately if symptoms develop earlier.>=5 days post-exposure (unless symptomatic)
Known exposure = close contact ≥15 minutes/24 hours.
Asymptomatic individuals without known exposure (hospitalization/procedure):
MIS-C suspected case criteria
MIS-C evaluation indicators (as listed):
MIS-C consideration: Consider MIS-C when subjective or documented fever (>38.0°C) AND clinical severity requiring hospitalization or resulting in death AND CRP >3.0 mg/dL OR new-onset manifestations in at least two organ categories (cardiac, shock, mucocutaneous, gastrointestinal, hematologic) AND detection of SARS-CoV-2 (nucleic acid/antigen up to 60 days prior to or during hospitalization) OR SARS-CoV-2 antibody associated with current illness OR close contact with a confirmed/probable COVID-19 case in the 60 days prior to hospitalization.see node text
Combines fever, severity, inflammatory marker, multisystem involvement, and recent SARS-CoV-2 exposure/testing as described in AAP/CDC guidance.
Evaluation and testing workflow
Recommended evaluation workflow for outpatient/ED and hospitalized patients:
Outpatient/ED evaluation: Evaluate children with persistent fever (≥3 days) who are moderately to severely ill with assessment of vital signs, perfusion, and oxygen saturation; consider initial laboratory screening (CBC with differential, urinalysis, ESR, CRP) and add ferritin, LDH, CMP, pro-BNP, troponin, fibrinogen based on clinical suspicion. Early pediatric infectious disease and rheumatology consultation and coordination with a pediatric referral center should be considered.persistent fever ≥3 days
None of these labs are specific; alternative diagnoses must be considered.
Severely ill patients: Severely ill or hemodynamically fragile patients (including compensated shock or shock) should be evaluated and treated in the ED/critical care setting and transferred to a referral center as needed; initiate subspecialty consultation but do not delay transfer.severe appearance or shock
Clinical stabilization and prompt transfer are priorities.
This policy applies to outpatient testing for medical decision-making and does not address testing that is mandated for non-clinical purposes such as work, school, state, or federal requirements.
Per FDA guidance and the policy evidence review, antibody (serologic) testing should not be used to diagnose or exclude acute SARS‑CoV‑2 infection. Serology is intended for surveillance, convalescent plasma donor evaluation, or specific clinician‑directed uses rather than acute diagnostic decisions.
Antigen and serologic assays must be performed exactly as authorized by the manufacturer and only on validated specimen types. Tests used on nonvalidated sample types or performed outside the manufacturer’s instructions (for example, using saliva for an assay authorized for nasal or nasopharyngeal swabs) have limited or unknown performance and are not supported.
The BioFire RP2.1 multiplex panel has limitations for certain pathogens: it should not be used when Bordetella pertussis is suspected because of the panel’s low sensitivity for B. pertussis; an FDA‑cleared, pertussis‑specific molecular test targeting the IS481 insertion sequence should be used instead.
WHO guidance recommends against performing viral culture or isolation as a routine diagnostic procedure for SARS‑CoV‑2; routine diagnosis should rely on nucleic acid amplification methods and other approved diagnostic tests.
The AMA advises that serology tests should not be used to determine an individual’s immune status, to issue 'immunity certificates,' or as the sole basis for returning to work or for other decisions about distancing. Serologic testing should be limited to population‑level studies, convalescent plasma donor evaluation, or other well‑defined clinician‑guided contexts.
Routine universal asymptomatic screening of healthcare facility patients with NAAT is not recommended. Preprocedure or preadmission asymptomatic screening should not be required for all patients; facility‑level risk assessment should guide targeted screening when appropriate rather than blanket universal testing.
When evaluating possible MIS‑C, no single laboratory study is diagnostic. Initial labs commonly used (CBC with differential, urinalysis, ESR, CRP, and others) are nonspecific, and alternative diagnoses such as pyelonephritis or appendicitis must be considered alongside clinical findings.
The cited reference list does not specify additional explicit coverage exclusions beyond those stated in the policy coverage sections.
Whole genome sequencing for reinfection (paired specimens from distinct lineages), SARS‑CoV‑2 genotyping, neutralization antibody testing, and antigen panels containing six or more antigens are described in the policy as not meeting coverage criteria and therefore are not covered.
Point‑of‑care serologic tests currently have limited supporting evidence of accuracy; meta‑analyses identified variable sensitivity and study bias. Available data do not support continued routine use of POC serological assays for diagnostic purposes.
Use of point‑of‑care serological tests as standalone diagnostics early in infection is not supported due to low sensitivity in the first week after symptom onset and the risk of false negatives; such tests should not replace molecular or antigen testing where acute diagnosis is required.
Guidance suggests against routine NAAT for asymptomatic individuals without known exposure prior to hospital admission or procedures; targeted testing may be considered in specific settings (eg, multibed rooms or congregate care) based on facility risk assessment and local epidemiology.
The reference citations as presented do not designate additional items as not medically necessary beyond those explicitly listed in the policy's 'Not Medically Necessary' and 'Does Not Meet Coverage' sections.
Coding and Reimbursement
Reimbursement coding rules (no explicit CPT/HCPCS list in this excerpt)mixed
No codes listed
Covered SARS-CoV-2 test CPT/HCPCS codesCPTCovered
86318
Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (eg, reagent strip).
86328
Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
86408
Neutralizing antibody, SARS-CoV-2; screen.
86409
Neutralizing antibody, SARS-CoV-2; titer.
86413
SARS-CoV-2 antibody, quantitative.
86769
Antibody; SARS-CoV-2.
87426
Infectious agent antigen detection by immunoassay technique; SARS-CoV-2.
87428
Infectious agent antigen detection by immunoassay technique; SARS-CoV-2 and influenza A/B.
87635
Infectious agent detection by nucleic acid; SARS-CoV-2, amplified probe technique.
87798
Infectious agent detection by nucleic acid, not otherwise specified; amplified probe technique, each organism.
1–10 of 12
1/2
Proprietary and miscellaneous SARS-CoV-2 test codesHCPCSCovered
0224U
Antibody, SARS-CoV-2, includes titer(s), when performed; Proprietary test: COVID-19 Antibody Test (Mount Sinai Laboratory).
0226U
Surrogate viral neutralization test (sVNT), SARS-CoV-2, ELISA, plasma, serum; Proprietary test: Tru-Immune (Ethos Laboratories/GenScript USA Inc).
0408U
Infectious agent antigen detection by bulk acoustic wave biosensor immunoassay, SARS-CoV-2; Proprietary test: Omnia SARS-CoV-2 Antigen Test (Qorvo Biotechnologies).
Non-CDC laboratory test for 2019-nCoV (COVID-19), any method.
Antigen panel maximum covered antigens
Maximum antigens coveredAntigen panel testing of up to 5 antigens meets coverage
Applicable settingIndividuals with signs and symptoms of a respiratory tract infection
Frequency/limit notePanel composition must be ≤5 antigens to qualify for coverage
Antigen panel non-covered threshold
Non-covered thresholdAntigen panel testing of 6 or more antigens does NOT meet coverage criteria
ImplicationPanels with ≥6 antigens should not be billed as covered under this policy
Provider Actions, Documentation, and Billing Guidance
Billing Rule
Single code per DOS — coding and documentation rules
AMA standard practice: do not include both a HCPCS and an AMA/CPT code for the same procedure on the same date of service (DOS). Only one procedure code per DOS will be reimbursed. Specimen collection codes for coronavirus testing are considered incidental and will not be reimbursed.
Only one procedure code per date of service will be reimbursed.
Specimen collection codes for coronavirus testing are incidental and will not be reimbursed.
Note
Pre-op PCR testing utility and pre-procedural test documentation
Routine pre-procedural PCR screening of asymptomatic patients has low yield and can add cost and delays to care. One study of 7,579 preprocedural tests found 0.41% positives, procedure delays or cancellations, a number needed to test of 244, and a cost per positive of approximately $11,573; standardized algorithms may improve cost-effectiveness. Testing should be considered based on clinical context and institutional protocols.
Background and Scope
Human coronaviruses include common cold strains, MERS‑CoV, SARS‑CoV, and SARS‑CoV‑2 (the cause of COVID‑19). Diagnostic methods include nucleic acid‑based assays (eg, RT‑PCR), antigen tests that detect viral proteins, and serologic tests that measure host antibody responses; NAATs are the primary method for confirming acute infection.
Definitions and Test Performance Terms
SARS-CoV-2 and RT-PCR (definitions)
SARS-CoV-2 definitionSARS-CoV-2 is the virus that causes COVID-19
RT-PCR definitionReverse transcription polymerase chain reaction (RT-PCR) is a nucleic acid-based test that detects viral RNA to diagnose acute infection
Testing noteRT-PCR detects viral RNA in respiratory specimens and is not suitable for determining past infection alone
MIS-C and MIS-A (definitions)
MIS-C definition (children)Multisystem inflammatory syndrome in children (MIS-C): illness in persons <21 years with fever, hospitalization, systemic inflammation, and multisystem involvement per CDC criteria
MIS-A (adults)MIS-A defined similarly for adults ≥21 years with hospitalization and specified clinical/laboratory criteria
Revision History
2024-08-27bibliography_updateLatest
Added/updated FDA Emergency Use Authorization references and guidance (Emergency Use Authorization framework).
2024-08-06bibliography_update
Included FDA Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay reference in bibliographic list.
2024-07-01bibliography_update
Policy Summary
Payerblue cross blue shield - tennessee
PolicyCoronavirus Testing in the Outpatient Setting
Policy CodePolicy N/A
Change TypeNo material changes
Effective Date
Next Review Date
Key ActionUse targeted testing: cover NAAT for symptomatic individuals and asymptomatic exposed persons (except within 90 days of prior infection); antigen tests covered every 48 hours for symptomatic persons; antigen panels covered up to 5 antigens.
Neutralization antibody testing for SARS-CoV-2 does NOT meet coverage.
chunk 4
Testing for other endemic coronaviruses: Testing for endemic coronaviruses (229E, NL63, OC43, HKU1) does NOT meet coverage.
chunk 4
Study quality, sample handling, patient selection, and assay type materially affect reported performance; point-of-care serologic tests have limited high-quality evidence and may have substantial bias in published studies.
n/a
Meta-analyses noted high risk of bias and variable PPA/NPA across platforms.
24-48 hours
IDSA suggests repeat NAAT 24-48 hours after initial negative in selected situations.
Testing of exposed asymptomatic individuals: IDSA/NIH suggest testing asymptomatic individuals with known/suspected exposures, typically at least 5 days after exposure (or immediately if symptoms develop earlier).>=5 days after exposure
Known exposure defined as close contact ≥15 minutes over 24 hours.
hospitalization >=24 hours
CDC definitions applied.
IDSA suggests against routine NAAT in asymptomatic individuals without known exposure who are being hospitalized or undergoing procedures (conditional, very low certainty); facility-level risk/benefit analysis recommended for select high-risk settings.
SHEA likewise recommends against universal asymptomatic screening.
Repeat NAAT to guide isolation or pre-procedure: Panels suggest against routinely repeating NAAT before procedures or to guide release from isolation because NAAT may detect RNA long after infectiousness; decisions should consider clinical context and procedure risk.
Balance risks of delay vs infectious risk.
Serologic testing uses: Serology is recommended for epidemiology/seroprevalence, convalescent plasma donor screening, MIS-C evaluation, and detection of prior infection (typically 3–5 weeks after symptom onset) but not for diagnosing acute infection in the first 2 weeks or for determining protective immunity.3-5 weeks after symptom onset for assessing prior infection
Prefer nucleocapsid-targeting assays when detecting prior infection is desired; AMA and IDSA caution against using serology for immunity certification.
Hospitalized patient testing: Hospitalized children suspected of MIS-C should have chest radiograph, EKG and troponin; if abnormal, consult pediatric cardiology and consider echocardiogram and/or cardiac MRI. Perform expanded laboratories (pro-BNP, triglycerides, CK, amylase, blood/urine cultures, D-dimer, PT/PTT/INR, CRP, ferritin, LDH, CMP, fibrinogen) and SARS-CoV-2 RT-PCR and serologic testing; send serology prior to IVIG administration if possible.hospitalization for suspected MIS-C
Testing and specialist involvement per AAP and ACR guidance.
Reference contextListed among items that DO NOT MEET COVERAGE CRITERIA
BioFire RP2.1 Limit of Detection (LoD)
BioFire RP2.1 LoD (heat-inactivated)500 copies/mL (100% detection at 20/20)
BioFire RP2.1 LoD (infectious isolate)160 copies/mL (100% detection at 20/20)
Equivalent TCID506.9 x 10^-2 TCID50/mL (heat-inactivated) and 1.1 x 10^-2 TCID50/mL (infectious isolate)
ePlex RP2 Limit of Detection (LoD)
ePlex RP2 LoD (TCID50)0.01 TCID50/mL
Approximate genomic copiesCorresponds to ~250 genomic copies/mL (by digital droplet PCR)
Performance basisLoD defined as lowest concentration detected ≥95% of the time in serial dilution testing (≥20 replicates per concentration)
C-reactive protein (CRP) threshold
CRP threshold for MIS-C consideration>3.0 mg/dL
ContextElevated CRP is part of CDC/AAP criteria for MIS-C evaluation alongside fever and multisystem involvement
UseConsidered an inflammatory marker supporting MIS-C diagnosis when combined with clinical criteria
Platelet count threshold
Platelet count threshold for MIS-C<150,000/µL
ContextThrombocytopenia listed among hematologic manifestations supporting MIS-C consideration
Diagnostic roleOne of several lab abnormalities; not specific and should be interpreted with clinical findings
Pre-procedural NAAT may be useful in some settings (e.g., multibed rooms, congregate units) but is not recommended universally for asymptomatic patients without exposure.
Testing close to surgery (ideally within 48–72 hours) is preferred when undertaken.
Documentation Required
Use FDA EUA-authorized multiplex panels
Use FDA EUA-authorized multiplex respiratory panels when clinically appropriate and when platform-specific requirements are met. Examples of EUA-authorized multiplex assays include BioFire RP2.1, QIAstat-Dx Respiratory SARS-CoV-2 Panel, ePlex Respiratory Pathogen Panel 2, cobas SARS-CoV-2 & Influenza A/B, Xpert Xpress SARS-CoV-2/Flu/RSV, and the CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay. Follow manufacturer and EUA instructions for intended use and specimen types.
Use multiplex panels that have FDA EUA for SARS-CoV-2 and influenza/RSV where indicated.
Adhere to platform-specific requirements (e.g., instrument compatibility such as BioFire FilmArray systems).
Documentation Required
Testing specimen-type compliance
Adhere to authorized specimen types and collection instructions for each assay. Failure to follow FDA labeling, an LDT validation, or EUA-authorized specimen types can adversely affect test performance and may result in claim denial. Document specimen type, collection method, and timing relative to symptom onset or exposure.
Only use specimen types authorized in the test's FDA EUA or validated in an LDT.
Document specimen collection details in the medical record; deviations without validation risk denial.
Note
Limits of negative RT-PCR — caution interpreting negative results
Negative RT-PCR (NAAT) results do not exclude SARS-CoV-2 infection. Negative results may occur due to improper collection, testing during early incubation, low viral load, or technical issues. Negative results should not be used as the sole basis for patient management decisions and must be combined with clinical assessment.
Consider timing of testing relative to exposure/symptom onset; viral RNA may be detectable up to 90 days but testing within incubation can be falsely negative.
Repeat or alternate testing may be indicated when clinical suspicion remains high.
Note
Caution interpreting negative antigen results and reflex testing considerations
Treat negative antigen test results as presumptive; confirm with an FDA-authorized molecular assay when necessary for clinical management. Antigen tests are less sensitive than NAATs, particularly in asymptomatic individuals; follow CDC guidance for repeat antigen testing or confirmatory NAAT as indicated.
Confirm negative antigen results with NAAT if clinical suspicion is high.
CDC recommends serial antigen testing (two tests 48 hours apart for symptomatic individuals; three tests 48 hours apart for asymptomatic) or use a NAAT to confirm.
Note
Pooling limitation
Pooling of samples can increase throughput but has efficiency limits. The FDA authorizations for pooled testing note that pooling is most efficient in low-prevalence settings and should not be used when the positivity rate for the tested population exceeds 25%.
Pooling strategies authorized for up to 4–7 samples depending on EUA; follow specific EUA instructions.
Do not use pooling if positivity rate >25% for the tested population.
Denial Risk
Risk of denial for routine asymptomatic screening
Routine NAAT screening of asymptomatic individuals without known exposure (including pre-admission or pre-procedure universal screening) is generally not recommended and may be subject to denial depending on medical necessity and benefit. Testing should be targeted to symptomatic individuals, those with known exposure, or situations where testing changes management.
IDSA suggests against routine NAAT of asymptomatic individuals without known exposure (conditional recommendation).
Document clinical rationale when testing asymptomatic patients to support medical necessity.
Documentation Required
Specimen timing relative to IVIG
For serologic testing in contexts like MIS-C, collect serology specimens prior to administration of IVIG, since IVIG can affect antibody test interpretation. Document timing of IVIG relative to specimen collection.
Serologic tests should be sent before IVIG administration; failure to do so can affect interpretation and downstream coverage decisions.
Note
Bibliographic references and EUA summaries — this section provides citation reference
This section provides citation references and sources for EUA summaries, FDA authorizations, and guideline recommendations; review the referenced EUA summaries and manufacturer instructions when implementing testing protocols.
Refer to FDA EUA summaries and manufacturer test instructions for performance characteristics and authorized use.
Bibliographic references and EUA documentation are provided in the reference list of this policy.
Documentation Required
Testing interpretation requirements
Testing interpretation requires clinical correlation: interpret results in the context of symptoms, exposure history, imaging, and timing of specimen collection. Antibody results must be interpreted relative to timing after symptom onset or exposure.
Negative or indeterminate NAAT results require clinical correlation and consideration of repeat testing if warranted.
Antibody results should account for timing (e.g., 3–5 weeks post-symptom onset for IgG) and vaccination history.
Step Therapy
Step therapy / test selection — none specified
Step therapy / test selection: there are no formal step-therapy requirements in this policy. Selection of test modality (NAAT, RT-LAMP, antigen) should be based on clinical context, specimen availability, timing relative to symptom onset, and test performance characteristics.
RT-LAMP and other molecular modalities may be used selectively where validated and appropriate.
Antigen tests may be useful for rapid screening but have lower sensitivity than NAATs; choose tests aligned with clinical needs.
Note
Testing choice after recent infection
Testing choice after recent infection: NAATs may detect residual RNA for up to 90 days after prior infection; for individuals with a prior positive NAAT within 90 days, CDC/NIH recommend preferential use of antigen tests rather than repeat NAAT to avoid detection of non-viable RNA.
Avoid NAAT within 90 days of prior positive NAAT unless new clinical signs suggest reinfection.
Prefer antigen testing for symptomatic recurrence within 90 days unless otherwise indicated.
Denial Risk
No procedural or billing denial triggers beyond documented rules
No additional procedural or billing denial triggers are specified in this section beyond the denial risks noted (e.g., non-medically indicated routine screening, failure to adhere to specimen-type requirements). Providers must document clinical rationale and follow manufacturer/EUA specimen and platform requirements to mitigate denial risk.
Denial risks center on lack of medical necessity and noncompliance with EUA/label specimen requirements.
Document clinical justification for testing to support coverage.
Key elementsFever, elevated inflammatory markers, multisystem organ involvement, and evidence of current/recent SARS-CoV-2 infection or exposure
Viral load and shedding
DefinitionViral load is the quantity of viral particles in a sample; higher loads correlate with transmissibility
TimingSARS-CoV-2 viral load typically peaks near symptom onset and decreases thereafter
Shedding durationMean RNA shedding in upper respiratory tract ~17 days (varies by specimen type and severity)
RT-PCR and antibody testing
RT-PCR purposeRT-PCR/NAAT detects viral RNA and is used to diagnose acute SARS-CoV-2 infection
Antibody testing purposeHost antibody tests detect IgM/IgA/IgG produced in response to infection and are not recommended to diagnose acute infection alone
Timing limitationAntibody tests have a delayed window after infection; serology is useful for assessing prior infection or in specific indications (e.g., MIS-C, serosurveys)
Antigen testing
DefinitionAntigen testing detects viral proteins (e.g., spike or nucleocapsid) to directly indicate presence of virus
UtilityRapid antigen tests offer faster turnaround but have lower sensitivity than NAATs, especially in asymptomatic persons or low viral load contexts
Confirmatory guidanceNegative antigen tests may require confirmatory molecular testing when clinical suspicion remains high
Antibody (serologic) testing
Serologic testing definitionAntibody (serologic) testing measures IgG, IgM, and IgA to infer prior or recent infection
LimitationsPresence of IgG does not necessarily indicate protective immunity or its duration; serology not recommended for diagnosing acute infection in first 2 weeks
Appropriate usesSerology appropriate for epidemiology/seroprevalence, MIS-C support, and convalescent plasma donor screening
Limit of Detection (LoD)
LoD definitionLimit of Detection (LoD) is the lowest concentration at which an assay detects the target ≥95% of the time
UnitsReported in copies/mL or TCID50/mL depending on assay and validation method
RelevanceLoD informs analytical sensitivity and comparability between assays for clinical interpretation
Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA)
PPA / NPA definitionPositive percent agreement (PPA) and negative percent agreement (NPA) report clinical performance versus a comparator method
UsePPA/NPA commonly reported for EUA validations and multiplex panel performance tables
ExampleePlex RP2 reported 100% PPA and 100% NPA in validation set (59/59 and 111/111)
RT-LAMP and opvCRISPR
RT-LAMP definitionReverse transcription loop-mediated isothermal amplification (RT-LAMP) is a rapid nucleic acid amplification method that can be combined with CRISPR-based detection (opvCRISPR)
AdvantagesFaster turnaround and potential point-of-care use without thermal cyclers; sensitivity varies with sample preparation and CT thresholds
LimitationsRequires optimization and may need RNA extraction step; performance declines at higher Ct values
NGS and Whole Genome Sequencing (WGS)
NGS / WGS definitionNext-generation sequencing (NGS) and whole genome sequencing (WGS) are methods to sequence SARS-CoV-2 genomes for detection and epidemiologic surveillance
ApplicationsUsed for outbreak investigation, variant identification, and public health surveillance; WGS may not meet coverage for reinfection diagnosis per policy
Ag-RDT self-test definitionAntigen-detection rapid diagnostic tests (Ag-RDTs) for self-testing allow individuals to test themselves for SARS-CoV-2
WHO performance standardWHO recommends Ag-RDTs meeting ≥80% sensitivity and ≥97% specificity among symptomatic individuals for self-testing
Implementation noteSelf-testing should be voluntary, quality-assured, and accompanied by clear messaging and linkage to care
Long COVID / Post-COVID conditions
DefinitionLong COVID (post-COVID conditions) is an infection-associated chronic condition present for at least 3 months after SARS-CoV-2 infection
Clinical approachDiagnosis is clinical using history and exam; no single laboratory test definitively diagnoses Long COVID
Common symptomsIncludes fatigue, cognitive impairment, dyspnea, persistent headache, sleep disturbance, smell/taste problems, GI symptoms
Rapid NAAT
Rapid NAAT definitionRapid NAAT refers to nucleic acid amplification tests with short turnaround times (commonly ≤30–60 minutes for the testing process)
ScopeTurnaround time refers to testing process only and excludes transport and reporting times
ExamplesRapid RT-PCR and rapid isothermal NAAT methodologies may qualify as rapid NAATs
Known exposure
Known exposure definitionClose contact defined as at least 15 minutes over a 24-hour period with someone with laboratory-confirmed COVID-19
High-risk exampleHousehold contact is considered high risk
Testing timingIDSA/NIH recommend testing exposed asymptomatic individuals at least 5 days after exposure unless symptoms develop earlier
MIS-C case definition (CSTE/CDC)
MIS-C case definition (CSTE/CDC)Person <21 years with fever, severe illness requiring hospitalization, CRP >3.0 mg/dL, multiorgan involvement (≥2 categories), and evidence of SARS-CoV-2 infection or exposure within 60 days
Key componentsFever, clinical severity, elevated inflammation, multisystem signs, and lab/epidemiologic evidence of SARS-CoV-2
Laboratory evidenceIncludes positive molecular or antigen tests up to 60 days prior or positive serology associated with current illness
MIS-C diagnostic indicators
MIS-C diagnostic indicatorsFeatures include subjective or documented fever >38.0°C, hospitalization or death, CRP >3.0 mg/dL, and hematologic abnormalities (e.g., platelets <150,000/µL)
Organ involvementAt least two organ categories (cardiac, mucocutaneous, GI, hematologic, shock) required
Evaluation roleLaboratory and clinical features are used together; none are specific alone
Tier 1 evaluation (ACR)
Tier 1 evaluation (ACR)First-line evaluation for MIS-C includes ESR, CRP, and testing for SARS-CoV-2 by PCR or serology
PurposeInitial screening to identify inflammation and evidence of SARS-CoV-2 exposure/infection
Follow-upAdditional labs and specialist consultation may be needed based on initial results
Emergency Use Authorization (EUA)
EUA definitionEmergency Use Authorization (EUA) are FDA-issued authorizations for diagnostic tests during the public health emergency
RelevanceMultiple diagnostic tests cited in policy are EUA-authorized with performance summaries in FDA documents
DocumentationEUA summaries and FDA guidance are referenced for assay performance and intended use